Leukemia Clinical Trials in Chicago

Showing 1741-1747 of 1,747 trials

Study for Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)

NCT00129948

This is a phase 2, single-arm, open-label, multi-center study to establish the safety and efficacy of Troxatyl™ (troxacitabine) administered as a continuous infusion for 5 days to subjects with AML.

Leukemia, Myeloid, Acute

SGX Pharmaceuticals, Inc.211 participantsStarted Jul 2005

La Jolla, California, United States • Los Angeles, California, United States • San Diego, California, United States +17 more locations

COMPLETEDPhase 22.2 miles

A Phase 2 Trial of Antisense Nucleotide to PKC-Alpha (LY900003, ISIS 3521) Plus Gemcitabine and Carboplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer.

NCT00042679

The purposes of this study are to determine the following: Whether LY900003 plus gemcitabine and carboplatin can make your tumor smaller or disappear, and for how long. If treatment with LY900003 plus gemcitabine and carboplatin can help you live longer. The safety of LY900003 plus gemcitabine and carboplatin and any side effects that might be associated with the combination of these three drugs. How LY900003 is distributed and broken down by your body when it is given with carboplatin and gemcitabine. Whether LY900003 affects the way gemcitabine and carboplatin are distributed and broken down by your body.

Carcinoma, Non-Small-Cell LungPulmonary NeoplasmsNeoplasms, Lung

Eli Lilly and CompanyStarted Jun 2002

Bakersfield, California, United States • Berkeley, California, United States • Torrance, California, United States +8 more locations

Study for Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)

A Phase 2 Trial of Antisense Nucleotide to PKC-Alpha (LY900003, ISIS 3521) Plus Gemcitabine and Carboplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer.

Leukemia Trials in Other Cities

Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.

CP-481,715 Nickel Allergy Study.

Phase I Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile Of Lenalidomide (Revlimid®, CC-5013) With Pemetrexed In Subjects With Advanced Non-Small Cell Lung Cancer

Treatment of Hallucinosis/Psychosis in Parkinson's Disease by an Investigational Drug

Study of DN-101 (Calcitriol) and Docetaxel in Subjects Previously Enrolled in Studies DN101-002 or DN101-004

Other Conditions in Chicago